Abstract
A fast growing sector with strong products and players - but what will the COPD/Asthma landscape look like 5 years from now?
The global asthma and COPD market is currently worth around US$20 billion.
The top twelve pharmaceutical products by value had combined global sales of
US$15.7 billion in 2005. Six brands had sales in excess of US$1 billion.
Combined sales of the top ten products were 21.1% higher than in 2004.
A number of older therapies, for asthma in particular, are widely available
generically and there is fierce competition in the market. The asthma market
accounts for the majority of the total and is valued at around US$15 billion.
The COPD market is currently valued at US$4 - US$5 billion and is set to
double in the next five years.
Future market growth will be driven by increasing disease awareness, an
increasing patient pool, both in the paediatric asthma sector and the ageing
population susceptible to COPD, and the launch of newer, more expensive
therapies targeting areas of high unmet clinical need. These will be offset
to some extent by the launch of new generics and the sales erosion of
monotherapies by combination products.
This report provides a complete insight to the prospects for companies and products that are driving this high growth US$20 billion sector.
View Cart
